异动解读｜Madrigal Pharmaceuticals盘前下跌6.74%，Q2财报超预期但每股亏损同比扩大

行情直击

Jul 30

7月30日，Madrigal Pharmaceuticals盘前下跌6.74%，报508.12美元/股，成交额75.48万美元。

消息面上，公司于当日盘前公布第二季度财报。数据显示，Q2产品收入3.64亿美元，超出市场预期的3.53亿美元；每股亏损1.99美元，优于分析师一致预期的2.50美元亏损。核心产品Rezdiffra（resmetirom）二季度净销售额3.643亿美元，同比增长71%，截至6月30日在用患者超4.9万人，较去年同期翻倍以上。

尽管营收和每股亏损均超预期，但公司每股亏损较去年同期的1.90美元扩大4.74%，净亏损达5793.9万美元，盈利能力边际恶化引发市场关注。此前富国银行给予跑赢大盘评级、目标价685美元，当前股价距目标价仍有较大空间，短期下跌或反映市场对盈亏改善节奏的分歧。

Madrigal Pharmaceuticals是一家生物制药公司，专注于代谢功能障碍相关脂肪性肝炎（MASH）新疗法，其药物Rezdiffra为每日一次口服肝脏导向甲状腺激素受体β激动剂。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1112230036"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112230036\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112230036?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-07-30 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112230036","market":"hk","top_or_hot":-1,"title":"异动解读｜Madrigal Pharmaceuticals盘前下跌6.74%，Q2财报超预期但每股亏损同比扩大","media":"行情直击","content":"<p><p>7月30日，Madrigal Pharmaceuticals盘前下跌6.74%，报508.12美元/股，成交额75.48万美元。</p><p>消息面上，公司于当日盘前公布第二季度财报。数据显示，Q2产品收入3.64亿美元，超出市场预期的3.53亿美元；每股亏损1.99美元，优于分析师一致预期的2.50美元亏损。核心产品Rezdiffra（resmetirom）二季度净销售额3.643亿美元，同比增长71%，截至6月30日在用患者超4.9万人，较去年同期翻倍以上。</p><p>尽管营收和每股亏损均超预期，但公司每股亏损较去年同期的1.90美元扩大4.74%，净亏损达5793.9万美元，盈利能力边际恶化引发市场关注。此前富国银行给予跑赢大盘评级、目标价685美元，当前股价距目标价仍有较大空间，短期下跌或反映市场对盈亏改善节奏的分歧。</p><p>Madrigal Pharmaceuticals是一家生物制药公司，专注于代谢功能障碍相关脂肪性肝炎（MASH）新疗法，其药物Rezdiffra为每日一次口服肝脏导向甲状腺激素受体β激动剂。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜Madrigal Pharmaceuticals盘前下跌6.74%，Q2财报超预期但每股亏损同比扩大</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜Madrigal Pharmaceuticals盘前下跌6.74%，Q2财报超预期但每股亏损同比扩大\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1059448697\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">行情直击 </p>\n<p class=\"h-time\">2026-07-30 20:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>7月30日，Madrigal Pharmaceuticals盘前下跌6.74%，报508.12美元/股，成交额75.48万美元。</p><p>消息面上，公司于当日盘前公布第二季度财报。数据显示，Q2产品收入3.64亿美元，超出市场预期的3.53亿美元；每股亏损1.99美元，优于分析师一致预期的2.50美元亏损。核心产品Rezdiffra（resmetirom）二季度净销售额3.643亿美元，同比增长71%，截至6月30日在用患者超4.9万人，较去年同期翻倍以上。</p><p>尽管营收和每股亏损均超预期，但公司每股亏损较去年同期的1.90美元扩大4.74%，净亏损达5793.9万美元，盈利能力边际恶化引发市场关注。此前富国银行给予跑赢大盘评级、目标价685美元，当前股价距目标价仍有较大空间，短期下跌或反映市场对盈亏改善节奏的分歧。</p><p>Madrigal Pharmaceuticals是一家生物制药公司，专注于代谢功能障碍相关脂肪性肝炎（MASH）新疗法，其药物Rezdiffra为每日一次口服肝脏导向甲状腺激素受体β激动剂。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1112230036","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112230036","pubTimestamp":1785413947,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"7月30日，Madrigal Pharmaceuticals盘前下跌6.74%，报508.12美元/股，成交额75.48万美元。消息面上，公司于当日盘前公布第二季度财报。核心产品Rezdiffra二季度净销售额3.643亿美元，同比增长71%，截至6月30日在用患者超4.9万人，较去年同期翻倍以上。Madrigal Pharmaceuticals是一家生物制药公司，专注于代谢功能障碍相关脂肪性肝炎新疗法，其药物Rezdiffra为每日一次口服肝脏导向甲状腺激素受体β激动剂。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc."},"translate_title":"Movement Interpretation | Madrigal Pharmaceuticals fell 6.74% premarket, Q2 earnings beat expectations but loss per share widened year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"7月30日，Madrigal Pharmaceuticals盘前下跌6.74%，报508.12美元/股，成交额75.48万美元。消息面上，公司于当日盘前公布第二季度财报。数据显示，Q2产品收入3.64亿美元，超出市场预期的3.53亿美元；每股亏损1.99美元，优于分析师一致预期的2.50美元亏损。核心产品Rezdiffra（resmetirom）二季度净销售额3.643亿美元，同比增长71%，截至6月30日在用患者超4.9万人，较去年同期翻倍以上。尽管营收和每股亏损均超预期，但公司每股亏损较去年同期的1.90美元扩大4.74%，净亏损达5793.9万美元，盈利能力边际恶化引发市场关注。此前富国银行给予跑赢大盘评级、目标价685美元，当前股价距目标价仍有较大空间，短期下跌或反映市场对盈亏改善节奏的分歧。Madrigal Pharmaceuticals是一家生物制药公司，专注于代谢功能障碍相关脂肪性肝炎（MASH）新疗法，其药物Rezdiffra为每日一次口服肝脏导向甲状腺激素受体β激动剂。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}